Cornerstone Search Group

CMO - Growing Oncology Pharma ($7Bn+ Market Cap) - 40 person team

• Atypical Small Company: (1) More resources from having fast-growing revenue and being profitable + (2) a history of developing approved drugs + (3) multiple modalities (bsAb/mAb, ADC, small molecule)
• Uniquely attractive company culture (positive, low ego, high collaboration, even keeled)
• Best of Both Worlds: small company feel + compensation stability of RSUs
• HYBRID - New York City Metropolitan Area
• Retained Search

Summary: Cornerstone Search Group has been retained by profitable, revenue generating, multi-billion market cap pharma with a highly collaborative, highly communicative, low ego, even-keeled, and resilient culture. Our client has a history of successful drug development (including a current fast-growing oncology blockbuster). They are seeking a Chief Medical Officer to guide a 40-person (and growing) team on an early stage, multi-modality pipeline (mAb, bsAb, ADC, small molecule, CAR-T) as well as to play an active BD role (i.e., research collaborations, in-licensing, acquisition). Our client is seeking an entrepreneurial MD or MD/PhD oncologist who has people management experience, a proclivity for early stage development, and will continue their cultural emphasis on collaboration, communication, positive realism, low bureaucracy, and high EQ.

LOCATION: New York Metro Area (on-site or hybrid)

This role is based in our client’s New York Metro Area office and will require occasional travel to its European headquarters. Our client prefers local candidates (i.e., NJ, NY, PA, CT) or candidates along the Eastern seaboard (e.g., MA, MD, DC, NC, DE).

RESPONSIBILITIES in a NUTSHELL:

• Accountable for the continued building and development of the company's pipeline.
• Lead (and continue to build) a team across Clinical Science/Development, Translational Medicine, Clinical Operations, Data Science, Regulatory, etc. in the US and EU
• Oversee the design and execution of oncology clinical trials strategy that incorporate global regulatory, medical, and commercial considerations.
• Develop relationships with academic research institutions and KOLs.
• Play active role in BD efforts including identifying and forging drug discovery research collaborations, in-licensing, co-development/co-marketing, and acquisition

Desired Skills / Qualifications / Experience / Behaviors:

• Oncology or Immunology medical training desired
• Previous pharma industry clinical development leadership experience across multiple assets
• Experience leading early stage oncology clinical strategy
• Experience with both biologics and small molecules is desired
• People management experience
• PhD and/or prior lab research experience is a plus.
• High emotional intelligence, the desire to make an impact, and the demonstrated courage to overcome obstacles when you believe strongly in something
• Clear and concise communication skills

CONTACT:

Corey S. Ackerman, JD | Senior Partner

[email protected]

http://www.linkedin.com/in/coreyackerman

973.656.0220 x716

CORNERSTONE SEARCH GROUP - Life Sciences Executive Search

1200 Morris Turnpike, Suite 3005, Short Hills, NJ (USA)

www.cornerstonesg.com

Cornerstone Search Group, recognized by Forbes as one of the "Top 100 Executive Search Firms" and by Hunt Scanlon as one of the "Top 50 Healthcare & Life Sciences Executive Search Firms", is a Life Sciences Executive Search firm that helps companies based around the world, ranging from startup biotechs to Top 10 pharmas, to find, attract, and hire talent for their US and globally based leadership positions (CxO and xVP levels) as well as their critical Director-level roles.

Representative List of Prior Retained Search Assignments:

• CEO | specialty pharma start-up
• CEO | regenerative medicine start-up
• US CEO | European multi-generational family-run pharma
• President/US Commercial Head | generics pharma
• CMO | late-stage public biotech
• CMO | mid-size pharma
• CCO | publicly-traded European oncology pharma
• CSO | mid-size global biotech
• SVP, Head of Global Medical Affairs | mid-size oncology company
• SVP, Head of Global Clinical Development | multi-TA mid-size pharma
• SVP, Head of Global Regulatory Affairs | late-stage Israeli biotech
• US General Counsel | publicly-traded EU commercial-stage rare disease pharma
• Group VP, Global Commercial Head | API Business Unit | Indian pharma
• VP, Data Science RWE | Top 5 Pharma
• VP, Head of Regulatory Affairs | Boston biotech
• VP, US Head of Regulatory Affairs | Top 20 Pharma
• VP, Head of R&D Operations | Boston biotech
• VP, Head of HEOR (Health Economics & Outcomes Research | Top CNS specialty pharma
• VP, Head of US HEOR & RWE | Top 5 Pharma
• VP, Head of Real-World Evidence | Top 5 pharma
• VP, Head of US HEOR | Top Oncology Pharma
• ED, Head of HEOR | Top West Coast Pharma
• VP, Head of Global Market Access | Top Oncology Specialty Pharma
• VP, Head of US Market Access | High-profile late stage biotech
• VP, Head of US Market Access | West Coast Late-Stage Public Biotech
• VP, Head of Heme/Onc Clinical Research | Public oncology biotech
• VP, Head of Clinical Development | late-stage anti-infectives UK pharma
• VP, Head of Global Drug Safety & PV | Chinese oncology biotech
• ED, Head of Clinical Operations | British VC-backed biotech
• ED, Global Commercial Strategy Franchise Head | Top rare disease Boston pharma
• ED, Head of Global Clinical Pharmacology | Public oncology biotech
• ED, Head of Global HEOR | Large US Pharma
• Head, Patient Advocacy | European commercial-stage rare disease biotech
• Medical Directors (Director/SD/ED levels) in Translational Medicine / Clinical Development / Medical Affairs / Drug Safety: 75+ retained assignments
• HEOR/RWE/Market Access (AD/Director/SD/ED levels): 100+ retained assignments

Cornerstone’s Privacy Policy: Cornerstone Search Group considers all inquiries, resume submissions, and any other personal information submitted to us as confidential information. This information will not be shared with any parties outside of Cornerstone Search Group without your prior permission.

CaVPoncHead3158

Keywords: cancer CAR-T antibody-drug conjugates bi-specific bispecific TKI solid tumor I-O immuno-oncology immunooncology